NL-OMON37147已完成不适用
An open-label, non-randomized, single-center, Phase I trial to investigate the mass balance and the metabolite profile of cilengitide in five healthy subjects - Cilengitide mass balance study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Merck
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male volunteers
- •18-45 years, inclusive
- •BMI: 18.5 * 29.9 kg/m2, inclusive
- •non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
- •In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study.
- •In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
招募中
1 期
Clinical trial of oral L-Arginine therapy for the patients with HAM/TSPHTLV-1-associated myelopathy/Tropical spastic paraparesisD015493JPRN-jRCTs071180068TAKASHIMA HIROSHI20
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.EUCTR2013-003579-36-ITBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.Pediatric patients with solid malignant tumors that are recurrent or refractory to standard therapy.EUCTR2013-003579-36-FRBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.RMS and other solid malignant tumors (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor) in which treatment with vincristine/irinotecan is considered backbone chemotherapy at relapse and a scientific rationale to combine irinotecan with regorafenib exists.MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-003579-36-GBBayer AG77
已完成
不适用
A single-center, non-randomized, open-label, one-sequence, two-period within-subject study to investigate the effect of Rifampicin on the pharmacokinetics of multiple doses of Balovaptan in healthy volunteersNL-OMON46088PRA Health F. Hoffmann-La Roche Ltd16